Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
132 hedge funds and large institutions have $623M invested in Cymabay Therapeutics in 2018 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 17 closing their positions.
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
14% more call options, than puts
Call options by funds: $766K | Put options by funds: $669K
12% more funds holding
Funds holding: 118 → 132 (+14)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
18% less capital invested
Capital invested by funds: $755M → $623M (-$132M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$9.71M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$7.63M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.06M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$5.76M |
| 5 |
BlackRock
New York
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$17.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.21M |
| 5 |
OA
Omega Advisors
New York
|
-$5.06M |
CBAY Hedge Fund Activity: Q3 2018 in Review
132 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2018, worth a combined $623M — down 18% from $755M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CBAY positions and 17 closed out — a net gain of 14 holders — while 40 added to existing stakes and 28 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $9.71M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $17.2M sold.
- 132 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2018, up from 118 in Q2 2018.
- Funds reported $623M of Cymabay Therapeutics stock for Q3 2018, down 18% quarter-over-quarter.
- 31 funds opened new Cymabay Therapeutics positions in Q3 2018 and 17 closed out, a net change of +14 holders.
- The largest Cymabay Therapeutics buyer in Q3 2018 was Eagle Asset Management, an estimated $9.71M added.
- The largest Cymabay Therapeutics seller in Q3 2018 was Avoro Capital Advisors, an estimated $17.2M sold.
Based on aggregated 13F filings for Q3 2018.